Unnamed: 0,title,date,stock,sentiment
18395.0,"Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.",2020-06-08 11:41:00-04:00,ACOR,positive
18396.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-05-14 07:40:00-04:00,ACOR,neutral
18397.0,"H.C. Wainwright Reiterates Neutral on Acorda Therapeutics, Lowers Price Target to $5",2020-05-06 07:39:00-04:00,ACOR,negative
18398.0,"Acorda Therapeutics Q1 EPS $(0.510) Misses $(0.350) Estimate, Sales $28.099M Miss $41.010M Estimate",2020-05-05 16:00:00-04:00,ACOR,negative
18399.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,ACOR,positive
18400.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-04 07:44:00-04:00,ACOR,neutral
18401.0,30 Stocks Moving in Monday's Pre-Market Session,2020-05-04 07:05:00-04:00,ACOR,neutral
18402.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ACOR,neutral
18403.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,ACOR,positive
18404.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,ACOR,negative
18405.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,ACOR,negative
18406.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,ACOR,neutral
18407.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,ACOR,negative
18408.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ACOR,positive
18409.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,ACOR,negative
18410.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,ACOR,negative
18411.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,ACOR,negative
18412.0,Acorda Therapeutics Sees FY20 Sales $130-$160M Vs. $149.21M Est.,2020-02-13 07:23:00-05:00,ACOR,neutral
18413.0,"Acorda Therapeutics Q4 EPS $(0.15) Beats $(0.40) Estimate, Sales $50.496M Beat $44.58M Estimate",2020-02-13 07:22:00-05:00,ACOR,neutral
18414.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,ACOR,neutral
18415.0,70 Biggest Movers From Friday,2020-01-27 04:02:00-05:00,ACOR,neutral
18416.0,52 Biggest Movers From Yesterday,2020-01-24 04:40:00-05:00,ACOR,neutral
18417.0,36 Stocks Moving In Thursday's Mid-Day Session,2020-01-23 14:05:00-05:00,ACOR,neutral
18418.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,ACOR,neutral
18419.0,21 Stocks Moving in Thursday's Pre-Market Session,2020-01-16 07:23:00-05:00,ACOR,neutral
18420.0,75 Biggest Movers From Yesterday,2020-01-16 04:37:00-05:00,ACOR,neutral
18421.0,Acorda Therapeutics shares are trading lower after the company filed a common stock offering by selling shareholders of roughly 9.6 million shares.,2020-01-15 16:25:00-05:00,ACOR,positive
18422.0,Acorda Therapeutics Files For ~9.6M Share Common Stock Offering By Selling Shareholders,2020-01-15 16:22:00-05:00,ACOR,positive
18423.0,Mid-Afternoon Market Update: OrganiGram Rises Following Q1 Results; Nektar Therapeutics Shares Plummet,2020-01-15 14:10:00-05:00,ACOR,positive
18424.0,Mid-Day Market Update: Concrete Pumping Falls On Weak Q4 Results; Fluent Shares Jump,2020-01-15 12:19:00-05:00,ACOR,negative
18425.0,36 Stocks Moving In Wednesday's Mid-Day Session,2020-01-15 12:07:00-05:00,ACOR,neutral
18426.0,Acorda Therapeutics shares are trading lower after the company issued FY19 and FY20 guidance.,2020-01-15 11:58:00-05:00,ACOR,neutral
18427.0,Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Reports Mixed Q4 Results,2020-01-15 10:09:00-05:00,ACOR,neutral
18428.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,ACOR,neutral
18429.0,"Acorda Sees Prelim. FY19 Total Net Product Revenue ~$178M, Sees FY20 Sales $130M-$160M vs $143.9M Est.",2020-01-15 07:03:00-05:00,ACOR,neutral
18430.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,ACOR,neutral
18431.0,15 Stocks Moving in Tuesday's Pre-Market Session,2020-01-07 07:48:00-05:00,ACOR,neutral
18432.0,53 Biggest Movers From Friday,2020-01-06 05:30:00-05:00,ACOR,neutral
18433.0,Mid-Afternoon Market Update: Dow Slides Over 200 Points; Landec Shares Drop On Q2 Earnings,2020-01-03 14:26:00-05:00,ACOR,neutral
18434.0,30 Stocks Moving In Friday's Mid-Day Session,2020-01-03 12:29:00-05:00,ACOR,neutral
18435.0,Mid-Day Market Update: Novan Falls On Failed Study; Acorda Therapeutics Shares Surge,2020-01-03 12:00:00-05:00,ACOR,negative
18436.0,Mid-Morning Market Update: Markets Open Lower; Lamb Weston Posts Upbeat Q2 Earnings,2020-01-03 10:13:00-05:00,ACOR,negative
18437.0,Acorda Therapeutics shares are trading higher after Point72 reported a 9.8% passive stake in the company.,2020-01-03 08:58:00-05:00,ACOR,positive
18438.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,ACOR,negative
18439.0,34 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-01-03 07:45:00-05:00,ACOR,neutral
18440.0,18 Stocks Moving in Friday's Pre-Market Session,2020-01-03 07:31:00-05:00,ACOR,neutral
18441.0,Point72 Reports 9.8% Passive Stake In Acorda Therapeutics,2020-01-02 17:17:00-05:00,ACOR,positive
18442.0,55 Biggest Movers From Yesterday,2019-12-31 04:21:00-05:00,ACOR,neutral
18443.0,Mid-Afternoon Market Update: Dow Down 150 Points; Savara Shares Spike Higher,2019-12-30 14:23:00-05:00,ACOR,positive
18444.0,Acorda Therapeutics shares are trading lower. Not seeing any news to justify the price action.,2019-12-30 13:27:00-05:00,ACOR,neutral
18445.0,32 Stocks Moving In Monday's Mid-Day Session,2019-12-30 12:13:00-05:00,ACOR,neutral
18446.0,Mid-Day Market Update: Dow Up 70 Points; Pintec Technology Shares Spike Higher,2019-12-27 12:23:00-05:00,ACOR,positive
18447.0,46 Stocks Moving In Friday's Mid-Day Session,2019-12-27 12:05:00-05:00,ACOR,neutral
18448.0,Acorda Therapeutics shares are trading lower as a potential sell-off after the stock increased roughly 40% yesterday.,2019-12-27 10:40:00-05:00,ACOR,positive
18449.0,Mid-Morning Market Update: Markets Mostly Higher; Flexion Receives FDA Nod For Zilretta Label Expansion,2019-12-27 10:26:00-05:00,ACOR,neutral
18450.0,31 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-27 08:13:00-05:00,ACOR,neutral
18451.0,28 Stocks Moving in Friday's Pre-Market Session,2019-12-27 07:47:00-05:00,ACOR,neutral
18452.0,60 Biggest Movers From Yesterday,2019-12-27 04:44:00-05:00,ACOR,neutral
18453.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-12-26 12:11:00-05:00,ACOR,neutral
18454.0,Acorda Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-12-26 10:59:00-05:00,ACOR,positive
18455.0,Acorda Therapeutics shares are trading higher. Not currently seeing any company-specific news.,2019-12-12 11:55:00-05:00,ACOR,positive
18456.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,ACOR,neutral
18457.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-12-04 12:02:00-05:00,ACOR,neutral
18458.0,Acorda Therapeutics shares are trading higher. Not currently seeing any news to justify the price action.,2019-12-03 11:50:00-05:00,ACOR,positive
18459.0,"Acorda Therapeutics shares are trading higher, potentially rebounding after the stock dropped ~39% over the past 10 trading sessions.",2019-11-21 15:05:00-05:00,ACOR,positive
18460.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,ACOR,positive
18461.0,Stocks That Hit 52-Week Lows On Wednesday,2019-11-20 10:37:00-05:00,ACOR,negative
18462.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,ACOR,positive
18463.0,"Acorda Therapeutics Announce That Jane Wasman, President, International & General Counsel, Is Resigning From The Company Effective At The End Of This Year",2019-11-12 07:58:00-05:00,ACOR,positive
18464.0,Biotech Stock On The Radar: Alkermes At A Crossroads,2019-11-07 11:53:00-05:00,ACOR,neutral
18465.0,Acorda Therapeutics shares are trading higher after the company reported better-than-expected Q3 sales results.,2019-11-05 11:47:00-05:00,ACOR,positive
18466.0,"Acorda Therapeutics Q3 GAAP EPS $(5.55), Sales $47.722M Beat $43.82M Estimate",2019-11-04 16:02:00-05:00,ACOR,neutral
18467.0,Acorda Q3 INBRIJA Net Sales $5M; Sees FY19 Year-End Cash Balance $225M+,2019-11-04 16:01:00-05:00,ACOR,neutral
18468.0,Acorda Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-11-01 11:04:00-04:00,ACOR,positive
18469.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,ACOR,neutral
18470.0,23 Biggest Movers From Yesterday,2019-11-01 07:30:00-04:00,ACOR,neutral
18471.0,Acorda Therapeutics shares are trading lower im sympathy with the weakness in the overall market.,2019-10-31 13:19:00-04:00,ACOR,negative
18472.0,27 Stocks Moving In Thursday's Mid-Day Session,2019-10-31 11:51:00-04:00,ACOR,neutral
18473.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-30 10:38:00-04:00,ACOR,negative
18474.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,ACOR,negative
18475.0,Stocks That Hit 52-Week Lows On Friday,2019-10-25 12:49:00-04:00,ACOR,negative
18476.0,21 Stocks Moving In Thursday's Mid-Day Session,2019-10-24 13:21:00-04:00,ACOR,neutral
18477.0,"Benzinga's Top Upgrades, Downgrades For October 24, 2019",2019-10-24 10:03:00-04:00,ACOR,positive
18478.0,Acorda Therapeutics shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight,2019-10-24 09:02:00-04:00,ACOR,positive
18479.0,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",2019-10-24 07:36:00-04:00,ACOR,neutral
18480.0,JP Morgan Downgrades Acorda Therapeutics to Underweight,2019-10-24 06:15:00-04:00,ACOR,positive
18481.0,41 Biggest Movers From Yesterday,2019-10-24 04:25:00-04:00,ACOR,neutral
18482.0,"Acorda Therapeutics Announces Corporate Restructuring; Co. To Reduce Headcount By 25%, Expects Annualized Cost Savings ~$21M",2019-10-23 16:03:00-04:00,ACOR,neutral
18483.0,Acorda Therapuetics shares are trading higher. Not seeing any news to justify the price action.,2019-10-23 11:50:00-04:00,ACOR,positive
18484.0,58 Biggest Movers From Friday,2019-10-14 03:51:00-04:00,ACOR,neutral
18485.0,Supreme Court Declines To Hear Acorda Therapeutics' Appeal In Patent Dispute Over Multiple Sclerosis Drug Ampyra,2019-10-07 09:34:00-04:00,ACOR,positive
18486.0,"Acorda's Inbrija Now Available In US Without Need For Medical Exception For ~66% Of Commercial, ~25% Of Medicare Plan Patients",2019-10-04 08:12:00-04:00,ACOR,neutral
18487.0,21 Stocks Moving in Thursday's Pre-Market Session,2019-10-03 08:07:00-04:00,ACOR,neutral
18488.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,ACOR,neutral
18489.0,58 Biggest Movers From Yesterday,2019-09-25 04:54:00-04:00,ACOR,neutral
18490.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,ACOR,negative
18491.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-09-24 12:54:00-04:00,ACOR,neutral
18492.0,Acorda Therapeutics shares are trading lower despite the company announcing that its Inbrija 33mg Inhalation powder and hard capsules was granted marketing authorization by the European Commission.,2019-09-24 12:16:00-04:00,ACOR,positive
18493.0,"Acorda Therapeutics Says European Commission Granted Marketing Authorization For Inbrija 33mg Inhalation Powder, Hard Capsules;  Marketing Authorization Approves Inbrija For Use In 28 EU Countries, As Well As Iceland, Norway And Liechtenstein",2019-09-24 09:57:00-04:00,ACOR,positive
18494.0,80 Biggest Movers From Yesterday,2019-09-11 05:11:00-04:00,ACOR,neutral
18495.0,84 Biggest Movers From Yesterday,2019-09-10 05:01:00-04:00,ACOR,neutral
18496.0,44 Stocks Moving In Monday's Mid-Day Session,2019-09-09 12:21:00-04:00,ACOR,neutral
18497.0,41 Stocks Moving In Friday's Mid-Day Session,2019-08-16 12:27:00-04:00,ACOR,neutral
18498.0,Stocks That Hit 52-Week Lows On Thursday,2019-08-15 11:29:00-04:00,ACOR,negative
18499.0,26 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-15 08:42:00-04:00,ACOR,neutral
18500.0,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings",2019-08-15 07:45:00-04:00,ACOR,neutral
18501.0,Acorda Therapeutics shares are trading lower after H.C. Wainwright downgraded the stock from Buy to Neutral and lowered the price target from $31 to $6.,2019-08-14 12:59:00-04:00,ACOR,negative
18502.0,Stocks That Hit 52-Week Lows On Wednesday,2019-08-14 12:46:00-04:00,ACOR,negative
18503.0,"Benzinga's Top Upgrades, Downgrades For August 14, 2019",2019-08-14 10:00:00-04:00,ACOR,positive
18504.0,"H.C. Wainwright Downgrades Acorda Therapeutics to Neutral, Lowers Price Target to $6",2019-08-14 08:00:00-04:00,ACOR,negative
18505.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,ACOR,negative
18506.0,Stocks That Hit 52-Week Lows On Tuesday,2019-08-13 11:08:00-04:00,ACOR,negative
18507.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-06 08:55:00-04:00,ACOR,neutral
18508.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,ACOR,negative
18509.0,82 Biggest Movers From Friday,2019-08-05 05:40:00-04:00,ACOR,neutral
18510.0,29 Healthcare Stocks Moving In Friday's After-Market Session,2019-08-02 20:51:00-04:00,ACOR,neutral
18511.0,Mid-Afternoon Market Update: Crude Oil Up Over 3%; Natural Grocers Shares Spike Higher,2019-08-02 14:44:00-04:00,ACOR,neutral
18512.0,60 Stocks Moving In Friday's Mid-Day Session,2019-08-02 13:43:00-04:00,ACOR,neutral
18513.0,"Stifel Maintains Hold on Acorda Therapeutics, Lowers Price Target to $7",2019-08-02 12:49:00-04:00,ACOR,negative
18514.0,Mid-Day Market Update: BlackLine Surges Following Upbeat Q2 Results; Glu Mobile Shares Slide,2019-08-02 12:27:00-04:00,ACOR,positive
18515.0,"Wedbush Reiterates Neutral on Acorda Therapeutics, Lowers Price Target to $7",2019-08-02 11:09:00-04:00,ACOR,negative
18516.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,ACOR,negative
18517.0,Mid-Morning Market Update: Markets Open Lower; Exxon Mobil Earnings Beat Estimates,2019-08-02 10:25:00-04:00,ACOR,negative
18518.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,ACOR,negative
18519.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,ACOR,negative
18520.0,Acorda Reports Received Positive CHMP Opinion For INBRIJA,2019-07-26 08:33:00-04:00,ACOR,positive
18521.0,Acorda Therapeutics Option Alert: Oct 18 $7 Puts Sweep (25) below Bid!: 630 @ $1.101 vs 1094 OI; Earnings 8/1 Before Open [est] Ref=$7.77,2019-07-02 09:37:00-04:00,ACOR,positive
18522.0,"The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO",2019-06-27 07:26:00-04:00,ACOR,negative
18523.0,"The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes",2019-06-13 07:44:00-04:00,ACOR,negative
18524.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,ACOR,positive
18525.0,55 Biggest Movers From Yesterday,2019-06-07 05:33:00-04:00,ACOR,neutral
18526.0,42 Stocks Moving In Thursday's Mid-Day Session,2019-06-06 12:36:00-04:00,ACOR,neutral
18527.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,ACOR,neutral
18528.0,66 Biggest Movers From Yesterday,2019-06-06 05:17:00-04:00,ACOR,neutral
18529.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-06-05 12:42:00-04:00,ACOR,neutral
18530.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,ACOR,positive
18531.0,"Wedbush Initiates Coverage On Acorda Therapeutics, Inc. - Common Stock with Neutral Rating, Announces $12 Price Target",2019-05-23 08:06:00-04:00,ACOR,neutral
18532.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,ACOR,positive
18533.0,"Acorda Therapeutics Q1 Adj. EPS $(0.56) Beats $(0.94) Estimate, Sales $41.334M Beat $33.04M Estimate",2019-05-02 06:17:00-04:00,ACOR,neutral
18534.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,ACOR,neutral
18535.0,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",2019-04-23 08:08:00-04:00,ACOR,positive
18536.0,"The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio",2019-04-18 07:42:00-04:00,ACOR,neutral
18537.0,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives",2019-04-16 08:10:00-04:00,ACOR,neutral
18538.0,"The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug",2019-04-12 07:47:00-04:00,ACOR,positive
18539.0,"The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering",2019-04-10 07:32:00-04:00,ACOR,positive
18540.0,Acorda To Present New Long-Term Data For INBRIJA At Academy Of Managed Care Pharmacy Annual Meeting,2019-03-19 07:06:00-04:00,ACOR,positive
18541.0,Acorda Therapeutics Reports Commercial Launch Of INBRIJA,2019-02-28 16:01:00-05:00,ACOR,neutral
18542.0,61 Biggest Movers From Friday,2019-02-19 05:14:00-05:00,ACOR,neutral
18543.0,52 Stocks Moving In Friday's Mid-Day Session,2019-02-15 12:35:00-05:00,ACOR,neutral
18544.0,"Acorda Therapeutics Late Thursday Reported Q4 EPS $0.45 Beats $(0.63) Estimate, Sales $69.152M Beat $52.54M Estimate",2019-02-15 12:21:00-05:00,ACOR,neutral
18545.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,ACOR,positive
18546.0,"The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",2019-02-14 07:50:00-05:00,ACOR,negative
18547.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,ACOR,neutral
18548.0,"Acorda Therapeutics Amended 13D Filing From Scopia Capital Shows Cut Stake From ~7.1M Shares To ~4.8M Shares, Or 10.1% Stake",2019-01-23 16:58:00-05:00,ACOR,positive
18549.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2018-12-31 09:00:00-05:00,ACOR,neutral
18550.0,"Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James",2018-12-26 09:45:00-05:00,ACOR,negative
18551.0,55 Biggest Movers From Monday,2018-12-26 04:38:00-05:00,ACOR,neutral
18552.0,40 Stocks Moving In Monday's Mid-Day Session,2018-12-24 12:15:00-05:00,ACOR,neutral
18553.0,Mid-Morning Market Update: Markets Open Lower; Vista Equity Partners to Acquire Mindbody For $36.50/Share,2018-12-24 10:43:00-05:00,ACOR,negative
18554.0,Acorda Therapeutics shares are trading higher after announcing FDA approval of INBRIJA.,2018-12-24 08:08:00-05:00,ACOR,positive
18555.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,ACOR,neutral
18556.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,ACOR,negative
18557.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,ACOR,positive
18558.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,ACOR,negative
18559.0,48 Biggest Movers From Yesterday,2018-12-12 05:14:00-05:00,ACOR,neutral
18560.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-12-11 12:29:00-05:00,ACOR,neutral
18561.0,Acorda Therapeutics shares are trading lower after Goldman Sachs lowered its rating on the stock from neutral to sell and announced a $10 price target.,2018-12-11 11:53:00-05:00,ACOR,negative
18562.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-12-11 08:03:00-05:00,ACOR,neutral
18563.0,"Goldman Sachs Downgrades Acorda Therapeutics to Sell, Lowers Price Target to $10",2018-12-11 05:58:00-05:00,ACOR,negative
18564.0,Germany-Based Pharmaceutical Company Grünenthal Acquires Global Commercial Rights For Qutenza Dermal Pain Patch From Acorda Therapeutics,2018-11-05 07:52:00-05:00,ACOR,negative
18565.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,ACOR,negative
18566.0,Acorda Therapeutics Raises FY18 AMPYRA Sales Guidance FRom $330M-$350M To Over $400M,2018-10-31 06:27:00-04:00,ACOR,neutral
18567.0,"Acorda Therapeutics Q3 Adj. EPS $0.17 Beats $(0.02) Estimate, Sales $142.814M Beat $82.81M Estimate",2018-10-31 06:26:00-04:00,ACOR,neutral
18568.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,ACOR,neutral
18569.0,"Acorda 8-K From Earlier Showed Co. Received Letters From FDA Related To Pre-Approval Inspections Of Co.'s Chelsea, Massachusetts Manufacturing Facility, Inbrija Inhaler Device Facility, Indicated Inspections Closed Without Need For Further Actions",2018-10-18 08:53:00-04:00,ACOR,neutral
18570.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-10-18 08:10:00-04:00,ACOR,neutral
18571.0,Acorda Therapeutics shares are trading higher after the company reported the FDA closed its inspections of facilities in Massachusettes without need for further action.,2018-10-18 07:53:00-04:00,ACOR,positive
18572.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,ACOR,neutral
18573.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs",2018-10-08 07:30:00-04:00,ACOR,neutral
18574.0,"Stifel Nicolaus Maintains Hold on Acorda Therapeutics, Lowers Price Target to $19",2018-10-05 07:29:00-04:00,ACOR,negative
18575.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,ACOR,negative
18576.0,"Acorda Therapeutics Reports FDA Extension Of INBRIJA New Drug Application Review Period PDUFA Date From Oct. 5, 2018 To Jan. 5, 2019",2018-09-13 07:01:00-04:00,ACOR,neutral
18577.0,51 Biggest Movers From Yesterday,2018-09-11 05:05:00-04:00,ACOR,neutral
18578.0,Mid-Afternoon Market Update: Dow Edges Lower; Acorda Therapeutics Shares Plunge,2018-09-10 14:41:00-04:00,ACOR,neutral
18579.0,30 Stocks Moving In Monday's Mid-Day Session,2018-09-10 12:30:00-04:00,ACOR,neutral
18580.0,Acorda Therapeutics shares are down 20.6% following a press release indicating US Court of Appeals upheld a Delaware decision to invalidate  4 AMPYRA patents.,2018-09-10 11:52:00-04:00,ACOR,positive
18581.0,Acorda Issues Press Release Highlighting US Appeals Court Upheld Delaware Decision To Invalidate 4 AMPYRA Patents In 2-1 Vote,2018-09-10 11:49:00-04:00,ACOR,neutral
18582.0,"Acorda Therapeutics Shares Down 21.3% After Earlier Report It Has Lost An Patent Court Appeal Ruling Regarding The Drug Ampyra, Affirming A Trial Ruling In Favor Of Teva and Mylan",2018-09-10 11:44:00-04:00,ACOR,positive
18583.0,"Cantor Fitzgerald Initiates Coverage On Acorda Therapeutics with Neutral Rating, Announces $32 Price Target",2018-08-23 07:08:00-04:00,ACOR,neutral
18584.0,Acorda Announces Management Transitions,2018-08-14 07:10:00-04:00,ACOR,neutral
18585.0,"Stifel Nicolaus Reinstates Hold on Acorda Therapeutics, Lowers Price Target to $25",2018-08-07 07:23:00-04:00,ACOR,negative
18586.0,UPDATE: Acorda Says Co. Signed Interim Deal With Hikma For Ampyra Time Period For Until Federal Circuit Issues Decision On Merits Of Appellate Proceeding,2018-08-03 07:19:00-04:00,ACOR,positive
18587.0,"UPDATE: Acorda Says Has Signed Interim Deal With Teva For Ampyra Time Period Until Aug. 31, 2018",2018-08-03 07:18:00-04:00,ACOR,neutral
18588.0,UPDATE: Acorda Says Mylan Will Be Permitted To Market Its Generic Version Of Ampyra In US Sometime In 2025 Or Earlier Under Certain Circumstances,2018-08-03 07:17:00-04:00,ACOR,positive
18589.0,"Acorda 8-K Shows Updates On Litigation With Mylan, Teva, West-Ward Pharma, Hikma Related To Ampyra Orange Book-Listed Patents: Entered Into Conditional Settlement Deal",2018-08-03 07:17:00-04:00,ACOR,negative
18590.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,ACOR,positive
18591.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-08-02 08:05:00-04:00,ACOR,neutral
18592.0,Acorda Sees FY18 AMPYRA Net Rev. Guidance Of $330-$350M,2018-08-02 06:16:00-04:00,ACOR,neutral
18593.0,"Acorda Therapeutics Q2 EPS $1.40 Beats $0.72 Estimate, Sales $153.302M Beat $138.31M Estimate",2018-08-02 06:16:00-04:00,ACOR,neutral
18594.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,ACOR,neutral
18595.0,50 Biggest Movers From Yesterday,2018-07-26 04:16:00-04:00,ACOR,neutral
18596.0,"UPDATE: Acorda, Alkermes v. Roxane Labs, Mylan, Teva Doc Shows 'On July 23, 2018, Acorda notified the court that ""Acorda plans to seek an emergency injunction on July 25, 2018 absent a change in circumstances.""'",2018-07-25 11:29:00-04:00,ACOR,negative
18597.0,"Hearing Acorda Loses Bid For Emergency Order Blocking Ampyra Copy, Co. Is Awaiting Decision On Validity Of Ampyra Patents",2018-07-25 11:19:00-04:00,ACOR,negative
18598.0,24 Stocks Moving In Friday's Mid-Day Session,2018-07-13 08:03:00-04:00,ACOR,neutral
18599.0,The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus,2018-06-30 17:32:00-04:00,ACOR,negative
18600.0,36 Biggest Movers From Friday,2018-06-11 04:37:00-04:00,ACOR,neutral
18601.0,Hearing Jefferies Gives Mid-Day Comment On Acorda Following Ampyra Hearing: 2+ Years Of Ampyra Exclusivity Could Be Worth $6/Share,2018-06-08 14:14:00-04:00,ACOR,positive
18602.0,30 Stocks Moving In Friday's Mid-Day Session,2018-06-08 12:31:00-04:00,ACOR,neutral
18603.0,"Upside In Acorda Being Attributed To Co. Appeal Hearing On Ampyra, Legal Dispute Research Firm MDC Financial Said Co. Did 'Exceptionally Well' On Its Oral Arguments During Hearing",2018-06-08 10:40:00-04:00,ACOR,negative
18604.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,ACOR,positive
18605.0,Acorda Announces EMA Validation Of MAA Submission Of INBRIJA For Treatment Of OFF Symptoms In Parkinson's Patients,2018-05-29 07:07:00-04:00,ACOR,neutral
18606.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,ACOR,neutral
18607.0,"Acorda Q1 EPS $(0.18) vs $(0.41) In Prior Year pEriod, Sales $106.16M Misses $129M Est.",2018-05-02 06:03:00-04:00,ACOR,negative
18608.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,ACOR,neutral
18609.0,Acorda Files Marketing Authorization Application for INBRIJA to the European Medicines Agency,2018-03-26 07:18:00-04:00,ACOR,neutral
18610.0,"Acorda Announces Agreement with Scopia Capital, Scopia to Appoint 2 Board Members",2018-02-28 07:12:00-05:00,ACOR,positive
18611.0,"Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More",2018-02-23 11:26:00-05:00,ACOR,neutral
18612.0,Acorda Announces FDA Acceptance of New Drug Application for INBRIJA,2018-02-20 06:01:00-05:00,ACOR,positive
18613.0,"Leerink Partners Global Healthcare Conf. Concludes Today, Presenters Include: Synlogic, Quanterix, Acorda Therapeutics, Bristol-Myers, Alnylam, and HCA Healthcare",2018-02-15 07:08:00-05:00,ACOR,neutral
18614.0,Acorda Therapeutics Sees FY18 AMPYRA Sales $330M-$350M,2018-02-15 06:10:00-05:00,ACOR,neutral
18615.0,"Acorda Therapeutics Reports Q4 EPS $0.61 vs $0.05 In Prior Year Period, Sales $167.2M vs $171M Est.",2018-02-15 06:02:00-05:00,ACOR,neutral
18616.0,34 Biggest Movers From Friday,2018-01-22 04:30:00-05:00,ACOR,neutral
18617.0,28 Stocks Moving In Friday's Mid-Day Session,2018-01-19 13:00:00-05:00,ACOR,neutral
18618.0,14 Stocks Moving In Friday's Pre-Market Session,2018-01-19 09:22:00-05:00,ACOR,neutral
18619.0,Benzinga Pro's 6 Stocks To Watch Today,2018-01-19 08:40:00-05:00,ACOR,neutral
18620.0,"Acorda Therapeutics Shares Indicated Up 8.8% Premarket Fri. Following Renewed Takeover Chatter; Thurs. Stock Rallied As Much As ~7%, Only to Sell Off During Afternoon Session; Report Fri. Morning Suggests Biogen, UCB Are Interested",2018-01-19 07:32:00-05:00,ACOR,positive
18621.0,UPDATE: STAT's Feuerstein Tweets 'Amend that. There are other reasons an $ACOR sale would be positive but Goodbye Ron is near the top.',2018-01-19 06:40:00-05:00,ACOR,positive
18622.0,STAT News' Adam Feuerstein Tweets 'Sale of $ACOR would be positive for no other reason than removing Ron Cohen from his CEO post. We'd all benefit from that.',2018-01-19 06:40:00-05:00,ACOR,positive
18623.0,"JP Morgan Healthcare Conference Continues Today, Presenters Include: Quidel, NovoCure, Acorda, PerkinElmer, Glaukos, IDEXX, MiMedx, Community Health, Global Blood Therapeutics, and Ultragenyx",2018-01-10 09:03:00-05:00,ACOR,positive
18624.0,"Acorda Therapeutics Shares Down 4.46%; Earlier Co. Reported Prelim. Q4 Sales $166M vs $173.82M, FY17 Sales $542M vs $573.68M Est.; Co. Sees FY18 $330-$350M vs $402.63M Est.",2018-01-08 10:45:00-05:00,ACOR,positive
18625.0,"Acorda Therapeutics Exploring Sale, According to Reuters",2018-01-05 15:33:00-05:00,ACOR,neutral
18626.0,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",2017-12-15 07:33:00-05:00,ACOR,positive
18627.0,Acorda Resubmits New Drug Application for INBRIJA,2017-12-07 06:07:00-05:00,ACOR,neutral
18628.0,28 Stocks Moving In Monday's Pre-Market Session,2017-11-20 08:06:00-05:00,ACOR,neutral
18629.0,Acorda Therapeutics Discontinues Development of Tozadenant,2017-11-20 07:03:00-05:00,ACOR,neutral
18630.0,Acorda Therapeutics Announces $53M of Payments for Royalty Rights,2017-11-17 07:03:00-05:00,ACOR,neutral
18631.0,"Benzinga's Top Upgrades, Downgrades For November 16, 2017",2017-11-16 10:02:00-05:00,ACOR,positive
18632.0,Stifel Nicolaus Downgrades Acorda Therapeutics to Hold,2017-11-16 07:11:00-05:00,ACOR,neutral
18633.0,Raymond James Downgrades Acorda Therapeutics to Underperform,2017-11-16 06:16:00-05:00,ACOR,neutral
18634.0,40 Biggest Movers From Yesterday,2017-11-16 04:46:00-05:00,ACOR,neutral
18635.0,Mid-Afternoon Market Update: OncoCyte Drops Following Q3 Results; Sorl Auto Parts Shares Jump,2017-11-15 14:31:00-05:00,ACOR,positive
18636.0,33 Stocks Moving In Wednesday's Mid-Day Session,2017-11-15 12:32:00-05:00,ACOR,neutral
18637.0,Mid-Day Market Update: YY Climbs After Strong Q3 Results; SandRidge Energy Shares Plummet,2017-11-15 12:05:00-05:00,ACOR,positive
18638.0,"UPDATE: Cowen Cuts Price Target On Acorda From $35 To $30, Maintains Outperform Rating",2017-11-15 11:43:00-05:00,ACOR,negative
18639.0,UPDATE: Cowen Sees Acorda's Inbrija As Undervalued,2017-11-15 11:42:00-05:00,ACOR,neutral
18640.0,"Cowen Issues Mid-Day Note On Acorda, Shares Down ~37%; Cowen Analyst Highlights 'We are skeptical a positive benefit-risk could be established, so we are removing Toz from our Acorda model'",2017-11-15 11:42:00-05:00,ACOR,positive
18641.0,Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates,2017-11-15 10:14:00-05:00,ACOR,positive
18642.0,"Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics",2017-11-15 08:59:00-05:00,ACOR,neutral
18643.0,Acorda Therapeutics Shares Down 31% Upon Resumption,2017-11-15 07:38:00-05:00,ACOR,positive
18644.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-11-15 07:08:00-05:00,ACOR,neutral
18645.0,Acorda Therapeutics Shares To Resume Trade At 7:30 a.m. EST,2017-11-15 07:04:00-05:00,ACOR,positive
18646.0,UPDATE: Acorda To Discuss Update For Tozadenant Development Program On Call At 8:30 a.m. EST Wed.,2017-11-15 07:03:00-05:00,ACOR,neutral
18647.0,"UPDATE: Acorda Says 'paused new enrollment [for tozadenant] in the long-term safety studies, pending further discussion with the independent DSMB, FDA'",2017-11-15 07:02:00-05:00,ACOR,positive
18648.0,"UPDATE: Acorda Says Co. Took Action 'in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death'",2017-11-15 07:01:00-05:00,ACOR,negative
18649.0,UPDATE: Acorda On Tozadenant Development: Co. 'has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson's disease',2017-11-15 07:01:00-05:00,ACOR,positive
18650.0,Acorda Offers Update On Toazdenant Development Program,2017-11-15 07:00:00-05:00,ACOR,neutral
18651.0,"BZ NOTE: Acorda Pres, CEO Ron Cohen To Present At Stifel's Healthcare Conference Wed., Nov. 15 At 10:45 a.m. EST",2017-11-15 06:58:00-05:00,ACOR,positive
18652.0,Acorda Shares Halted News Pending,2017-11-15 06:57:00-05:00,ACOR,positive
18653.0,"13F Filing From Baker Bros Shows Increased Stake In Acceleron Pharma, New Stake In Acorda Therapeutics",2017-11-14 15:51:00-05:00,ACOR,positive
18654.0,"Oppenheimer Initiates Coverage On Acorda Therapeutics with Perform Rating, Announces $27.00 Price Target",2017-11-09 08:51:00-05:00,ACOR,neutral
18655.0,Acorda Sees FY17 AMPYRA Sales Of $535-$545M,2017-10-31 06:06:00-04:00,ACOR,neutral
18656.0,"Acorda Reports Q3 EPS $0.43 vs $0.65 Est., Sales $141M vs $150M Est.",2017-10-31 06:06:00-04:00,ACOR,neutral
18657.0,Acorda Therapeutics Says it is Working with the FDA to Resubmit its Inbrija NDA,2017-09-27 07:03:00-04:00,ACOR,neutral
18658.0,Acorda Adopts a Shareholder Rights Plan,2017-09-01 07:00:00-04:00,ACOR,positive
18659.0,13D From Scopia Capital On Acorda Therapeutics Shows 18.2% Stake,2017-08-31 16:55:00-04:00,ACOR,neutral
18660.0,Acorda Therapeutics Shares Move Higher With Other Stocks Over Last 10 Mins; Traders Attributing Move Higher To Positive Alert From Source On Agora Financial,2017-08-30 12:58:00-04:00,ACOR,positive
18661.0,Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet,2017-08-29 14:32:00-04:00,ACOR,positive
18662.0,15 Biggest Mid-Day Losers For Tuesday,2017-08-29 12:57:00-04:00,ACOR,negative
18663.0,Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide,2017-08-29 12:05:00-04:00,ACOR,positive
18664.0,Mid-Morning Market Update: Markets Open Lower; Best Buy Tops Q2 Estimates,2017-08-29 10:13:00-04:00,ACOR,positive
18665.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-08-29 08:07:00-04:00,ACOR,neutral
18666.0,"Adam Feuerstein Tweets: $ACOR suffers embarrassing, costly delay to FDA review of Parkinson's drug statnews.com/2017/08/29/aco… via @statnews",2017-08-29 08:05:00-04:00,ACOR,negative
18667.0,Acorda Receives Refusal to File Letter from FDA for INBRIJA Regarding its Previously Filed NDA,2017-08-29 07:05:00-04:00,ACOR,neutral
18668.0,"Activists Gonna Activate: Hedge Funds Send Letters To Acorda, Taubman Centers Boards",2017-08-07 14:41:00-04:00,ACOR,neutral
18669.0,18 Biggest Mid-Day Gainers For Monday,2017-08-07 12:33:00-04:00,ACOR,neutral
18670.0,"UPDATE: Acorda Says 'initiating a sale process or a public review of strategic alternatives at this point would destabilize operations, hinder our ability to execute...and risk significantly devaluing the Company'",2017-08-07 11:32:00-04:00,ACOR,positive
18671.0,UPDATE: Acorda Says 'We believe that a sale of the Company at the present time would not adequately compensate shareholders for the potential benefits of the Company's late-stage programs',2017-08-07 11:31:00-04:00,ACOR,positive
18672.0,UPDATE: Acorda Says Board 'unanimously determined that focusing on our two late-stage programs in Parkinson's disease (INBRIJA™ and tozadenant) and maximizing AMPYRA is the best path forward...',2017-08-07 11:31:00-04:00,ACOR,positive
18673.0,UPDATE: Acorda Says 'Board of Directors and management team are committed to acting in the best interests of shareholders and all Acorda stakeholders',2017-08-07 11:30:00-04:00,ACOR,positive
18674.0,8-K From Acorda Therapeutics Shows Response To Scopia Capital Mgmt.,2017-08-07 11:30:00-04:00,ACOR,neutral
18675.0,"Scopia Capital Has Submitted Letter To Acorda Board Uging Pursuit Of Strategic Alternatives, Including Sale of Co., Formation Of Special Committee",2017-08-07 08:52:00-04:00,ACOR,positive
18676.0,13D From Scopia Capital On Acorda Therapeutics Shows 16.5% Stake,2017-08-07 08:36:00-04:00,ACOR,neutral
18677.0,"Jefferies Initiates Coverage On Acorda Therapeutics with Hold Rating, Announces $22.00 Price Target",2017-07-11 06:05:00-04:00,ACOR,neutral
18678.0,Acorda Submits NDA To FDA For INBRIJATM,2017-06-29 16:03:00-04:00,ACOR,neutral
18679.0,"Acorda Therapeutics CEO Ron Cohen Buys 20,000 @ Avg Price: $16.95 -Form4",2017-06-20 15:54:00-04:00,ACOR,neutral
18680.0,Acorda Therapeutics Says it Filed an Appeal for 4 Invalidated Patents,2017-06-09 06:57:00-04:00,ACOR,neutral
18681.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-06-06 08:12:00-04:00,ACOR,neutral
18682.0,Acorda Therapeutics Offers Phase 3 Data for CVT-301 Showing Significantly Improved Motor Function During OFF Periods in Parkinson's Disease,2017-06-05 16:02:00-04:00,ACOR,positive
18683.0,"Adam Feuerstein Tweets: $ACOR call —Stifel analyst Tom Schrader apologized to management. ""Sorry for how this all turned out, but that's the business.""

Vomit.",2017-04-27 08:44:00-04:00,ACOR,positive
18684.0,"Acorda Q1 EPS $(0.08) vs $0.09 Est, Sales $119.39M vs $127.34M Est",2017-04-27 08:35:00-04:00,ACOR,neutral
18685.0,Acorda Therapeutics to Cub Headcount by 20%,2017-04-05 06:03:00-04:00,ACOR,neutral
18686.0,12 Biggest Mid-Day Losers For Monday,2017-04-03 13:06:00-04:00,ACOR,negative
18687.0,Acorda Therapeutics Down  4.76% Premarket Following Downgrades From JPMorgan and Janney,2017-04-03 08:54:00-04:00,ACOR,neutral
18688.0,22 Stocks Moving In Monday's Pre-Market Session,2017-04-03 08:35:00-04:00,ACOR,neutral
18689.0,Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher,2017-03-31 14:46:00-04:00,ACOR,positive
18690.0,"Acorda Therapeutics Shares Resume Trade, Down 23.27%",2017-03-31 13:00:00-04:00,ACOR,positive
18691.0,Acorda Therapeutics Shares to Resume Trade at 1 p.m. EDT,2017-03-31 12:37:00-04:00,ACOR,positive
18692.0,"Acorda Issues Press Release Confirming US District Court Decision to Invalidate 4 AMPYRA Patents, Says Co. Will Appeal Ruling",2017-03-31 12:31:00-04:00,ACOR,neutral
18693.0,Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient,2017-03-31 12:15:00-04:00,ACOR,neutral
18694.0,Acorda Halted News Pending,2017-03-31 12:09:00-04:00,ACOR,neutral
18695.0,"Forward Pharma Shares Resume, Continue Lower, Now Down 32%",2017-03-31 11:41:00-04:00,ACOR,neutral
18696.0,"Acorda Shares Resume, Plunge Lower, Now Down 26%; Halted on Second Circuit Breaker",2017-03-31 11:40:00-04:00,ACOR,neutral
18697.0,"Forward Pharma Shares Plunge 14%, Halted on Circuit Breaker, Likely on the Heels of Acorda News, Move",2017-03-31 11:39:00-04:00,ACOR,positive
18698.0,"UPDATE: Acorda Shares Halted on Circuit Breaker, Down 14%",2017-03-31 11:38:00-04:00,ACOR,positive
18699.0,"Adam Feuerstein Tweets: $ACOR ""District Court finds all four Acorda Ampyra patents invalid for obviousness — filing"" per StreetAccount.",2017-03-31 11:37:00-04:00,ACOR,neutral
18700.0,"Adam Feuerstein  @adamfeuerstein now $ACOR ""District Court finds all four Acorda Ampyra patents invalid for obviousness — filing"" per StreetAccount",2017-03-31 11:36:00-04:00,ACOR,neutral
18701.0,Acorda Therapeutics Falls to Low of $22.85; Halted on CB,2017-03-31 11:36:00-04:00,ACOR,negative
18702.0,Acorda Therapeutics Spikes to High of $29.75 on Volume,2017-03-29 14:13:00-04:00,ACOR,neutral
18703.0,Acorda Therapeutics Study Shows Participants Receiving CVT-301 Had No Change in Pulmonary Function vs the Control Group,2017-03-29 06:06:00-04:00,ACOR,negative
18704.0,8 Biggest Price Target Changes For Monday,2017-03-13 10:02:00-04:00,ACOR,neutral
18705.0,"Benzinga's Top Upgrades, Downgrades For March 13, 2017",2017-03-13 09:34:00-04:00,ACOR,positive
18706.0,"Janney Capital Upgrades Acorda Therapeutics To Buy, Raises Price Target To $38",2017-03-13 06:49:00-04:00,ACOR,neutral
18707.0,Acorda Therapeutics Higher Off Favorable Patent Ruling Related To Ampyra,2017-03-09 15:55:00-05:00,ACOR,positive
18708.0,Acorda Press Release Confirms PTAB Upheld Four AMPYRA Patents,2017-03-09 15:43:00-05:00,ACOR,neutral
18709.0,"Acorda Shares Resume Trade, Continue Higher, Now Up 7.4%",2017-03-09 14:53:00-05:00,ACOR,positive
18710.0,Traders Attributing Move Higher in Acorda to Patent Ruling Related to Ampyra,2017-03-09 14:51:00-05:00,ACOR,neutral
18711.0,"Acorda Therapeutics Shares Halted on Circuit Breaker, Now Up ~7%",2017-03-09 14:48:00-05:00,ACOR,positive
18712.0,Acorda Therapeutics Shares Up $2+ Over Last Min.,2017-03-09 14:47:00-05:00,ACOR,positive
18713.0,Watch These 7 Huge Put Purchases In Monday Trade,2017-03-06 04:23:00-05:00,ACOR,positive
18714.0,Benzinga's Option Alert Recap From March 3,2017-03-03 16:40:00-05:00,ACOR,positive
18715.0,Option Alert: Accorda Therapeutics Mar 24.0 Puts Sweep: 1614 @  ASK  $2.40: 2709 traded vs 361 OI:  Earnings 4/27 Before Open (est)  $27.20 Ref,2017-03-03 15:28:00-05:00,ACOR,positive
18716.0,"Benzinga's Top Upgrades, Downgrades For February 15, 2017",2017-02-15 09:39:00-05:00,ACOR,positive
18717.0,Goldman Sachs Upgrades Acorda Therapeutics To Neutral,2017-02-15 08:36:00-05:00,ACOR,neutral
18718.0,"Acorda Therapeutics Q4 EPS $0.05 vs $0.11 Est, Revenue $132M vs $137.9M Est",2017-02-14 06:04:00-05:00,ACOR,neutral
18719.0,"Earnings Scheduled For February 14, 2017",2017-02-14 04:49:00-05:00,ACOR,neutral
18720.0,Watch These 5 Huge Put Purchases In Friday Trade,2017-02-10 04:26:00-05:00,ACOR,positive
18721.0,Benzinga's Option Alert Recap From February 9,2017-02-09 16:42:00-05:00,ACOR,positive
18722.0,Option Alert: Acorda Mar $20 Put; 6800 @Bid @$3.20,2017-02-09 11:56:00-05:00,ACOR,positive
18723.0,"Acorda Therapeutics Reports SPAN-PD Trial for CVT-301 Met Primary Endpoint, Showing Statistical Significant Improvement of Motor Function; Sees NDA Submission Q2",2017-02-09 06:11:00-05:00,ACOR,positive
18724.0,"Acorda Q4 AMPYRA Sales $132M, Sees FY 2017 AMPYRA Sales $535M to $545M",2017-01-09 06:03:00-05:00,ACOR,neutral
18725.0,January Will Feature Some Of The Market's Most Influential Events,2016-12-30 15:36:00-05:00,ACOR,positive
18726.0,12 Biggest Mid-Day Losers For Monday,2016-12-19 13:10:00-05:00,ACOR,negative
18727.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2016",2016-12-19 09:08:00-05:00,ACOR,positive
18728.0,"Janney Capital Initiates Coverage On Acorda Therapeutics at Neutral, Announces $23.00 Target",2016-12-19 06:16:00-05:00,ACOR,neutral
18729.0,"Cantor Fitzgerald Initiates Coverage On Acorda Therapeutics at Neutral, Announces $21.00 Target",2016-12-16 08:47:00-05:00,ACOR,neutral
18730.0,Mid-Day Market Update: Headwaters Surges On Acquisition News; Cubic Shares Slide,2016-11-21 11:32:00-05:00,ACOR,positive
18731.0,Mid-Morning Market Update: Markets Open Higher; Symantec To Acquire Lifelock,2016-11-21 10:22:00-05:00,ACOR,neutral
18732.0,15 Stocks Moving In Monday's Pre-Market Session,2016-11-21 08:33:00-05:00,ACOR,neutral
18733.0,Acorda Therapeutics to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties,2016-11-21 06:06:00-05:00,ACOR,negative
18734.0,Stifel Healthcare Conference Continues Today,2016-11-16 10:26:00-05:00,ACOR,neutral
18735.0,"Acordia Q3 EPS $(0.04) vs $0.11 Est, Revenue $135.6M vs $134.0M Est",2016-10-27 06:25:00-04:00,ACOR,neutral
18736.0,Acorda Sees Q3 AMPYRA Net Revenue $128.8M to $117.0M,2016-10-27 06:24:00-04:00,ACOR,neutral
18737.0,Acordia Reports Data Published In Science Translational Medicine For CVT-301 For Parkinson's Treatment,2016-10-13 07:07:00-04:00,ACOR,neutral
18738.0,Leerink Swann Assumes Acorda Therapeutics at Market Perform,2016-10-04 06:29:00-04:00,ACOR,neutral
18739.0,Acorda CFO Leaves Company,2016-10-04 06:00:00-04:00,ACOR,neutral
18740.0,Stocks Hitting   52-Week Lows,2016-09-29 10:32:00-04:00,ACOR,negative
18741.0,Monday Market Wrap: Stocks Fall Nearly 1% To Start Week,2016-09-26 17:01:00-04:00,ACOR,neutral
18742.0,Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade,2016-09-26 14:30:00-04:00,ACOR,positive
18743.0,Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News,2016-09-26 12:49:00-04:00,ACOR,negative
18744.0,The Street's Adam Feuerstein Tweets: $ACOR down bc last week's court hearings on Ampyra patent challenge didn't go well. Increased chance of generic launch in 2018.,2016-09-26 11:47:00-04:00,ACOR,negative
18745.0,Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss,2016-09-26 10:04:00-04:00,ACOR,negative
18746.0,Option Alert: Acorda Therapeutics Jan 20 $23 Puts at the bid: 500 @ 3.05 vs. Open Interest 0,2016-08-25 12:38:00-04:00,ACOR,positive
18747.0,"Acorda Therapeutics Enters Settlement Agreement with Accord Healthcare, Intas Pharma Over Ampyra",2016-08-15 08:42:00-04:00,ACOR,positive
18748.0,"8-K from Acorda Therapeutics Shows Settlement Deal with Alkem Labs, Ascend Labs for Resolving Patent Litigation Related to Ampyra ER Tablets",2016-08-03 07:39:00-04:00,ACOR,positive
18749.0,Acorda Raises FY16 Adj. EPS Outlook from $3.39-$3.49 to $3.43-$3.53,2016-07-28 06:23:00-04:00,ACOR,neutral
18750.0,Acorda Reaffirms FY16 AMPYRA Sales $475M-$485M,2016-07-28 06:21:00-04:00,ACOR,neutral
18751.0,"Acorda Reports Q2 Adj. EPS $0.07 vs $0.31 in Same Qtr. Last Year, Sales $127.458M vs $113.7M YoY",2016-07-28 06:21:00-04:00,ACOR,neutral
18752.0,Acorda Names Dr. Burkhard Blank Chief Medical Officer,2016-07-01 07:02:00-04:00,ACOR,neutral
18753.0,Hearing Acorda Therapeutics Has Said US Appeals Court Denied Mylan's Request for Rehearing in Ampyra Case,2016-06-21 07:42:00-04:00,ACOR,negative
18754.0,US Court of Appeals for Federal Circuit Denied Request by Mylan for Rehearing of Court's Previous Decision to Uphold Lower Court Ruling that Acorda's ANDA Litigation vs Mylan can Continue in District Court of Delaware,2016-06-21 07:34:00-04:00,ACOR,negative
18755.0,Acorda Therapeutics Enters into Credit Agreement With JPMorgan Chase Bank,2016-06-02 07:40:00-04:00,ACOR,positive
18756.0,"Acorda Dips 2%, Company Says It Will Discontinue Development Of Nasal Spray",2016-05-20 09:13:00-04:00,ACOR,neutral
18757.0,Acorda to Discontinue of PLUMIAZ for Treatment of Epilepsy Seizure Clusters,2016-05-20 06:03:00-04:00,ACOR,neutral
18758.0,Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters,2016-05-20 06:02:00-04:00,ACOR,neutral
18759.0,Biotie Therapies to Delist US Listing,2016-05-18 09:04:00-04:00,ACOR,neutral
18760.0,Biotie Therapies Cancels All Treasury Shares Held by Company,2016-05-18 04:26:00-04:00,ACOR,positive
18761.0,Biotie Therapies to Delist ADS from Nasdaq Global Select Market,2016-05-18 04:16:00-04:00,ACOR,neutral
18762.0,Acorda Sells Off to Low of $26.02 on Vol,2016-05-16 10:58:00-04:00,ACOR,negative
18763.0,"Acorda Q1 EPS $0.07 vs $0.08 est, Revenue $109.6M vs $115.4M est",2016-04-28 06:18:00-04:00,ACOR,neutral
18764.0,Acorda Reports 93.9% Stake in Biotie Therapies in 13D,2016-04-25 16:40:00-04:00,ACOR,neutral
18765.0,Acorda Therapeutics Sees Improvements In Phase 2b Clinical Study Of CVT301,2016-04-20 08:10:00-04:00,ACOR,positive
18766.0,"Acorda Reports Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson's Disease Published in Movement Disorders , Showed Significantly Greater Improvement In Motor Function vs. Placebo",2016-04-20 07:04:00-04:00,ACOR,positive
18767.0,Accorda Therapeutics Announces Final Results Of Tender Offer On Biotie Therapies,2016-04-13 10:14:00-04:00,ACOR,neutral
18768.0,Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology Annual Meeting,2016-04-07 07:00:00-04:00,ACOR,neutral
18769.0,"Goldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension",2016-03-30 08:17:00-04:00,ACOR,neutral
18770.0,"Goldman Sachs Initiates Coverage on Acorda Therapeutics at Neutral, Announces $23.00 PT",2016-03-30 06:45:00-04:00,ACOR,neutral
18771.0,Acorda Therapeutics Says it has Completed Phase 1 Single-dose Pharmacokinetic studies for Three Separate Once-daily Formulations of Dalfampridine,2016-03-29 07:13:00-04:00,ACOR,neutral
18772.0,What's Going On With Kyle Bass And Biogen?,2016-03-23 14:23:00-04:00,ACOR,neutral
18773.0,Acorda Therapeutics Announces Federal Court Upheld Ruling Against Mylan that NDA Can Continue,2016-03-21 07:31:00-04:00,ACOR,neutral
18774.0,Acorda Announces Patent Trials and Appeal Board (PTAB) Institutes IPRs of AMPYRA Patents,2016-03-11 15:54:00-05:00,ACOR,neutral
18775.0,Hearing Kyle Bass Coalition IPR Review Instituted against Challenged Acorda '703 Ampyra Patent,2016-03-11 14:38:00-05:00,ACOR,negative
18776.0,Acorda Therapeutics Sells Off to Low of $34.26 on Volume,2016-03-11 14:32:00-05:00,ACOR,negative
18777.0,"Acorda Therapeutics Announces Will Begin Voluntary Public Tender Offer for All of Issued, Outstanding Shares, ADS, Options, Units, Warrants in Biotie Therapies Corp. on Mar. 11, '16",2016-03-10 08:40:00-05:00,ACOR,positive
18778.0,Acorda Therapeutics Announces Update on its Program to Develop CVT-427 as Acute Treatment for Migraine using ARCUS Inhaled Delivery Technology,2016-03-08 07:06:00-05:00,ACOR,neutral
18779.0,Acorda Files Tender Offer Document Relating to Public Tender Offer for Biotie Therapies with Finnish Financial Supervisory Authority,2016-03-03 04:31:00-05:00,ACOR,positive
18780.0,Stocks To Watch During Cowen's 36th Annual Healthcare Conference,2016-03-01 13:21:00-05:00,ACOR,neutral
18781.0,Acorda Therapeutics Sees FY Revenue $475M to $485M vs $516M est,2016-02-11 06:09:00-05:00,ACOR,neutral
18782.0,"Acorda Therapeutics Q4 EPS $0.28 vs $0.22 est, Revenue $122M vs $128M est",2016-02-11 06:09:00-05:00,ACOR,neutral
18783.0,"8-K Filing Shows Acorda Therapeutics To Offer 2,250,900 Shares To Initial Purchaser In Private Placement",2016-01-25 17:05:00-05:00,ACOR,positive
18784.0,Acorda Therapeutics Confirms It Entered Into A Patent Litigation Settlement Deal With Par Pharma,2016-01-21 09:29:00-05:00,ACOR,negative
18785.0,8-K from Acorda Therapeutics Shows Co. Entered Settlement Deal with Par Pharma Related to Pending Patent Litigation Related to Ampyra ER Tablets,2016-01-20 17:18:00-05:00,ACOR,negative
18786.0,"Benzinga's M&A Chatter for Tuesday January 19, 2015",2016-01-19 21:26:00-05:00,ACOR,neutral
18787.0,Mid-Afternoon Market Update: US Stocks Turn Red; Crude Oil Falls Over 3%,2016-01-19 14:48:00-05:00,ACOR,negative
18788.0,Mid-Day Market Update: Dow Surges 150 Points; Progressive Waste Shares Spike Higher,2016-01-19 12:21:00-05:00,ACOR,negative
18789.0,Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Views,2016-01-19 10:05:00-05:00,ACOR,positive
18790.0,Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development,2016-01-19 09:40:00-05:00,ACOR,positive
18791.0,Acorda to Acquire Biotie Therapies for $25.60/ADS,2016-01-19 04:15:00-05:00,ACOR,neutral
18792.0,Acorda Therapeutics Sees FY2016 Sales $475.0M-485.0M vs $518.40M Est,2016-01-11 07:33:00-05:00,ACOR,neutral
18793.0,"Aegis Capital Maintains Buy on Acorda Therapeutics, Raises PT to $52.00",2016-01-06 11:37:00-05:00,ACOR,neutral
18794.0,Kyle Bass Explains The 'Patent Trolls' Situation In The Pharma Industry,2016-01-02 20:38:00-05:00,ACOR,neutral
18795.0,8-K from Acorda Therapeutics Shows Co. Entered Settlement Deal with Aurobindo Pharma to Resolve Pending Patent Litigation,2015-12-10 07:10:00-05:00,ACOR,positive
18796.0,"Acorda Starts Phase 1 Clinical Trial of CVT-427, Inhaled Therapy for Acute Treatment of Migraines",2015-12-03 07:01:00-05:00,ACOR,neutral
18797.0,"Acorda Therapeutics Q3 EPS $0.31 vs $0.15 est, Revenue $117M vs $115.5M est",2015-10-22 06:04:00-04:00,ACOR,neutral
18798.0,8-K from Acorda Therapeutics Shows Settlement Deal with Sun Pharma Related to Patent Litigation,2015-10-21 08:48:00-04:00,ACOR,negative
18799.0,Acorda to Present New rHIgM22 and AMPYRA Data at 31st Congress of European Committee for Treatment and Research in MS,2015-10-07 07:05:00-04:00,ACOR,neutral
18800.0,Benzinga's Volume Movers,2015-10-05 10:39:00-04:00,ACOR,neutral
18801.0,Acorda Therapeutics 8-K Says Co. Agrees With Actavis to Resolve Pending Patent Litigation,2015-10-05 07:07:00-04:00,ACOR,positive
18802.0,"Acorda Therapeutics 8-K Filing Shows Company WIll Oppose Requests To Institute For IPRS, Will Oppose Full Proceedings And Defend Patents",2015-09-03 16:29:00-04:00,ACOR,neutral
18803.0,Benzinga's Top #PreMarket Gainers,2015-08-26 08:15:00-04:00,ACOR,positive
18804.0,Mid-Morning Market Update: Markets Open Higher; Best Buy Tops Q2 Views,2015-08-25 10:47:00-04:00,ACOR,positive
18805.0,Benzinga's Volume Movers,2015-08-25 10:45:00-04:00,ACOR,neutral
18806.0,Morning Market Gainers,2015-08-25 09:49:00-04:00,ACOR,neutral
18807.0,Benzinga's Top #PreMarket Gainers,2015-08-25 08:14:00-04:00,ACOR,positive
18808.0,Acorda Reports Patent Trials and Appeal Board (PTAB) Denies Both IPRs of AMPYRA Patents,2015-08-24 17:42:00-04:00,ACOR,negative
18809.0,Evercore ISI's Mark Schoenebaum Comments on Acorda Following ADROCA Filing: Highlights Patent Trial and Appeal Board of USPTO Ruled Not to Institute Two Intellectual Property Rights on Co.'s Ampyra,2015-08-24 17:28:00-04:00,ACOR,positive
18810.0,Acorda Therapeutics Indicated Up 12% After Hours On News That Kyle Bass Denied Intellectual Property Rights Patent Number'685,2015-08-24 16:59:00-04:00,ACOR,positive
18811.0,Acorda Data on Inhaled Levodopa Therapy CVT-301 Recognized at International Congress of Parkinson's Disease and Movement Disorders,2015-06-24 07:02:00-04:00,ACOR,neutral
18812.0,Biotech Stocks Worth Taking A Look At,2015-06-19 06:56:00-04:00,ACOR,positive
18813.0,Acorda Reports Data Inhaled Levodopa Therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders,2015-06-16 07:01:00-04:00,ACOR,neutral
18814.0,Guggenheim Securities Initiates Coverage on Acorda Therapeutics at Neutral,2015-06-09 08:58:00-04:00,ACOR,positive
18815.0,Morning Market Losers,2015-06-02 09:51:00-04:00,ACOR,negative
18816.0,Acorda Therapeutics Shares Fall 9% Premarket Following Report of Clinical Hold,2015-06-02 08:51:00-04:00,ACOR,positive
18817.0,UPDATE 8K Filing: Acorda Therapeutics Puts Hold On 1B Clinical Trail Of Cimaglermin Alfa Based On Hepatotoxicity Occurence,2015-06-02 08:50:00-04:00,ACOR,neutral
18818.0,Acorda Therapeutics Puts Hold On 1B Clinical Trail Of Cimaglermin Alfa Based On Hepatotoxicity Occurence,2015-06-02 08:50:00-04:00,ACOR,neutral
18819.0,Acorda Q1 EPS $0.15 vs $0.14 est,2015-04-30 06:08:00-04:00,ACOR,neutral
18820.0,Piper Jaffray Assumes Acorda Therapeutics at Neutral,2015-04-22 08:59:00-04:00,ACOR,neutral
18821.0,Acorda Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting,2015-04-22 07:32:00-04:00,ACOR,neutral
18822.0,Acorda Reports Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting,2015-04-22 07:31:00-04:00,ACOR,neutral
18823.0,Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent,2015-04-20 16:09:00-04:00,ACOR,positive
18824.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,ACOR,neutral
18825.0,Second IPR from Kyle Bass on Acorda,2015-02-27 09:50:00-05:00,ACOR,neutral
18826.0,This Analyst Is Defending Acorda Therapeutics; Shares Still Down 7% In A Week,2015-02-17 17:55:00-05:00,ACOR,positive
18827.0,Benzinga's Top Initiations,2015-02-12 10:05:00-05:00,ACOR,positive
18828.0,MLV & Co. Initiates Acorda Therapeutics With Buy,2015-02-12 09:28:00-05:00,ACOR,neutral
18829.0,"MLV & Co. Initiates Coverage on Acorda Therapeutics at Buy, Announces $58.00 PT",2015-02-12 09:10:00-05:00,ACOR,neutral
18830.0,"Acorda Therapeutics Q4 EPS $0.46 vs $0.49, Sales $117.9M vs $118.4M",2015-02-12 06:09:00-05:00,ACOR,neutral
18831.0,"Earnings Scheduled For February 12, 2015",2015-02-12 04:29:00-05:00,ACOR,neutral
18832.0,Stifel Says Acorda Therapeutics Decline Is 'A Buying Opportunity',2015-02-11 17:42:00-05:00,ACOR,positive
18833.0,Acorda Therapeutics Spikes Higher; Court Filing Being Circulated,2015-02-10 14:10:00-05:00,ACOR,neutral
18834.0,Gilead Could Miss Earnings (Hint: Watch Drug Sales),2015-02-02 22:27:00-05:00,ACOR,negative
18835.0,Acorda Announces Positive Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis,2015-02-02 07:07:00-05:00,ACOR,positive
18836.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,ACOR,neutral
18837.0,Acorda Therapeutics Says Deferring Further Development of NP-1998 for Neuropathic Pain in 2015,2015-01-12 06:17:00-05:00,ACOR,negative
18838.0,Acorda Therapeutics Sees FY2015 Sales $405.0M-420.0M vs $413.07M Est,2015-01-12 06:16:00-05:00,ACOR,neutral
18839.0,J.P Morgan Just Chimed In With Ratings On Biotech Stocks,2015-01-06 16:34:00-05:00,ACOR,neutral
18840.0,US Stock Futures Up Ahead Of Economic Data,2014-12-15 07:23:00-05:00,ACOR,neutral
18841.0,Acorda Initiates Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits,2014-12-15 07:07:00-05:00,ACOR,neutral
18842.0,Benzinga's Top Initiations,2014-12-05 09:21:00-05:00,ACOR,positive
18843.0,Goldman Sachs Initiates Acorda Therapeutics With Neutral,2014-12-05 08:57:00-05:00,ACOR,neutral
18844.0,"Goldman Sachs Initiates Coverage on Acorda Therapeutics, Inc. at Neutral, Announces $40.00 PT",2014-12-05 05:46:00-05:00,ACOR,neutral
18845.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,ACOR,neutral
18846.0,8 Attractive U.S. Healthcare Stocks With Low PEG Ratios,2014-11-06 13:49:00-05:00,ACOR,positive
18847.0,"Acorda Therapeutics, Inc. Reports Q3 EPS of $0.28 vs $0.05 Est; Revenue of $106.0M vs $94.56M Est",2014-10-30 06:02:00-04:00,ACOR,neutral
18848.0,Acorda Shares Move Higher After-Hours on CEO Appearance on Mad Money with Jim Cramer,2014-10-02 18:39:00-04:00,ACOR,negative
18849.0,Acorda Shares Move Higher; Will Appear on Mad Money Tonight with Jim Cramer,2014-10-02 09:57:00-04:00,ACOR,negative
18850.0,"Benzinga's M&A Chatter for Wednesday September 24, 2014",2014-09-24 21:09:00-04:00,ACOR,neutral
18851.0,Stocks Gain While Dollar Reaches Highest Level Since 2010,2014-09-24 17:03:00-04:00,ACOR,positive
18852.0,Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results,2014-09-24 15:54:00-04:00,ACOR,positive
18853.0,Shares of Acorda Edge to Fresh Session Highs as Cowen Has Just Issued Mid-Day Note Boosting Price Target from $52 to $65,2014-09-24 13:50:00-04:00,ACOR,positive
18854.0,U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast,2014-09-24 13:17:00-04:00,ACOR,negative
18855.0,Markets Edge Lower; KB Home Posts Downbeat Results,2014-09-24 10:49:00-04:00,ACOR,negative
18856.0,Benzinga's Volume Movers,2014-09-24 10:14:00-04:00,ACOR,neutral
18857.0,Morning Market Movers ,2014-09-24 09:40:00-04:00,ACOR,neutral
18858.0,Shares of Acorda Trading Up ~7%,2014-09-24 08:21:00-04:00,ACOR,positive
18859.0,Shares of Acorda Therapeutics to Resume Trade at 7:55 a.m. EDT,2014-09-24 07:32:00-04:00,ACOR,positive
18860.0,UPDATE: Acorda Will Receive Rights to Phase 3 Parkinson's Disease Treatment,2014-09-24 07:28:00-04:00,ACOR,neutral
18861.0,Acorda to Purchase Civitas Therapeutics for $525M,2014-09-24 07:25:00-04:00,ACOR,neutral
18862.0,Shares of Acorda Therapeutics Halted News Pending,2014-09-24 07:21:00-04:00,ACOR,positive
18863.0,Events for the Week of Sept. 8-12,2014-09-10 14:34:00-04:00,ACOR,neutral
18864.0,Shares of Acorda Therapeutics Quiet Following FBR Note Suggesting Co.'s Evaluation of Five Options Could Create Situation Allowing for Inversion Strategy,2014-08-12 14:42:00-04:00,ACOR,positive
18865.0,Acorda Therapeutics Reports Q2 Adjusted EPS of $0.42 Which May Not Compare $0.15 Est; Revenue of $87.40M Which May Not Compare $91.42M Est,2014-07-31 06:13:00-04:00,ACOR,neutral
18866.0,"Watch Acorda Shares as Pres, CEO Ron Cohen Currently Talking on CNBC",2014-07-10 08:47:00-04:00,ACOR,positive
18867.0,Markets Edge Higher; Alcoa Profit Beats Street View,2014-07-09 10:20:00-04:00,ACOR,positive
18868.0,Acorda Therapeutics Says Expects to Initiate Phase 3 Clinical Trial Studying Use of Dalfampridine by Year's End -8-K,2014-07-09 06:09:00-04:00,ACOR,neutral
18869.0,Acorda Therapeutics Announces Notification Of ANDA Filing For AMPYRA,2014-06-26 06:03:00-04:00,ACOR,neutral
18870.0,Benzinga's Volume Movers,2014-06-18 10:17:00-04:00,ACOR,neutral
18871.0,Market Wrap For June 17: Markets Higher Ahead Of Fed Decision,2014-06-17 16:30:00-04:00,ACOR,neutral
18872.0,"Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session",2014-06-17 15:16:00-04:00,ACOR,neutral
18873.0,Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics Shares Tumble,2014-06-17 12:41:00-04:00,ACOR,positive
18874.0,Mid-Morning Market Update: Markets Gain; FactSet Posts Rise In Revenue,2014-06-17 10:27:00-04:00,ACOR,positive
18875.0,Morning Market Losers ,2014-06-17 09:55:00-04:00,ACOR,negative
18876.0,Filing from Acorda Therapeutics Shows Automatic Mixed Securities Shelf,2014-06-16 16:06:00-04:00,ACOR,positive
18877.0,Acorda Therapeutics Reports Q1 EPS of $0.02 vs $0.10 Est; Revenue of $72.50M vs $81.28M Est,2014-05-06 06:04:00-04:00,ACOR,neutral
18878.0,Acorda Therapeutics Announces FDA CRL for PLUMIAZ NDA,2014-05-02 06:14:00-04:00,ACOR,neutral
18879.0,"Canaccord Genuity Initiates Coverage on Acorda Therapeutics, Inc. at Hold, Announces $37.00 PT",2014-04-17 07:46:00-04:00,ACOR,neutral
18880.0,"FBR Capital Upgrades Acorda Therapeutics, Inc. to Outperform, Raises PT to $47.00",2014-04-14 08:52:00-04:00,ACOR,neutral
18881.0,Acorda to Initiate Phase 3 Study of Dalfampridine-QD In People With Post-Stroke Walking Deficits in H2 2014,2014-04-14 07:20:00-04:00,ACOR,neutral
18882.0,"Acorda Therapeutics Reports Q4 EPS of $0.15, Inline; Revenue of $92.60M vs $90.78M Est",2014-02-13 06:05:00-05:00,ACOR,neutral
18883.0,"Citigroup downgraded Acorda Therapeutics, Says Fundamentals Have Reversed For the Near-Term",2014-01-06 12:10:00-05:00,ACOR,neutral
18884.0,"Citigroup Downgrades Acorda Therapeutics, Inc. to Neutral, Lowers PT to $33.00",2014-01-06 07:11:00-05:00,ACOR,negative
18885.0,Acorda Therapeutics Announces European Patent Office Upholds Fampridine Patent,2013-12-19 07:02:00-05:00,ACOR,neutral
18886.0,Acorda Presents New Diazepam Nasal Spray Data at 67th Annual Meeting of American Epilepsy Society ,2013-12-09 07:11:00-05:00,ACOR,neutral
18887.0,Acorda Shares Spike Higher During CEO Appearance with Jim Cramer on Mad Money,2013-11-05 18:22:00-05:00,ACOR,negative
18888.0,"MKM Partners Upgrades Acorda Therapeutics, Inc. to Neutral",2013-11-01 08:45:00-04:00,ACOR,neutral
18889.0,Acorda Therapeutics Reports Q3 Adjusted EPS of $0.38 vs $0.13 Est; Revenue of $84.92M vs $90.01M Est,2013-10-31 06:26:00-04:00,ACOR,neutral
18890.0,"Acorda Therapeutics Reports Data from Phase 2 Trial of Delfampridine-ER, Says Data Consistent with Prior Trials",2013-10-14 07:58:00-04:00,ACOR,neutral
18891.0,Acorda Therapeutics Names Michael Rogers CFO,2013-10-07 07:00:00-04:00,ACOR,neutral
18892.0,"Acorda Therapeutics, Inc. Reports Q2 Adjusted EPS of $0.25 vs $0.09 Est; Revenue of $87.10M vs $82.57M Est",2013-08-01 06:18:00-04:00,ACOR,neutral
18893.0,First Study of Diazepam Nasal Spray in People with Epilepsy Shows Feasibility of Dosing During Seizure ,2013-06-26 07:06:00-04:00,ACOR,neutral
18894.0,Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA(R) Covering a Range of Dosage Strengths,2013-05-20 07:30:00-04:00,ACOR,positive
18895.0,Acorda Therapeutics Announces New US Patent for AMPYRA,2013-05-20 07:05:00-04:00,ACOR,neutral
18896.0,"MKM Partners Downgrades Acorda Therapeutics, Inc. to Sell",2013-05-02 13:11:00-04:00,ACOR,neutral
18897.0,"Acorda Therapeutics, Inc. Reports Q1 EPS of $0.09 vs $0.13 Est; Revenue of $71.90M vs $80.71M Est",2013-05-02 06:20:00-04:00,ACOR,neutral
18898.0,Acorda Therapeutics Spikes Higher,2013-04-17 13:41:00-04:00,ACOR,neutral
18899.0,"Market Wrap for Tuesday, April 16: Stock Market Rebounds Strongly From Monday's Sharp Losses ",2013-04-16 16:21:00-04:00,ACOR,negative
18900.0,"Market Wrap for Monday, April 15: Major Sell-Off Sweeps Wall Street; Gold Plunges to 2-Year Low",2013-04-15 16:33:00-04:00,ACOR,negative
18901.0,"Mid-Afternoon Market Update: Explosions Rock Downtown Boston, Authorities Unsure if Explosive Devices",2013-04-15 15:41:00-04:00,ACOR,negative
18902.0,"Mid-Day Market Update: Sprint Surges On Dish Network Offer, AuRico Gold Tumbles",2013-04-15 13:15:00-04:00,ACOR,neutral
18903.0,Stocks Hitting 52-Week Highs,2013-04-15 11:23:00-04:00,ACOR,neutral
18904.0,Acorda Therapeutics Announces Positive AMPYRA Phase 2 Data in People with Post-Stroke Deficits ,2013-04-15 08:03:00-04:00,ACOR,positive
18905.0,Acorda Says FDA Granted Fast Track Designation for GFF2,2013-03-07 11:22:00-05:00,ACOR,positive
18906.0,"Acorda Therapeutics, Inc. Reports Q4 EPS of $0.24 vs $0.15 Est; Revenue of $81.47M vs $78.90M Est",2013-02-13 06:15:00-05:00,ACOR,neutral
18907.0,Acorda Therapeutics Could Be a Stock to Watch in 2013,2013-02-04 15:21:00-05:00,ACOR,neutral
18908.0,Editor of Little Bear Blog is Long Acorda Therapeutics,2013-01-11 11:49:00-05:00,ACOR,neutral
18909.0,"Acor CEO Cohen: 'Over 70,000 People with MS have Tried Ampyra'",2013-01-09 18:23:00-05:00,ACOR,neutral
18910.0,Acor CEO Cohen: 'Investing in Economical Medications is the Better Way to Go',2013-01-09 18:20:00-05:00,ACOR,positive
18911.0,"Acor CEO Cohen: 'Physical Therapy is Useful for People Who have had Strokes, But Not the Same as Medication'",2013-01-09 18:20:00-05:00,ACOR,positive
18912.0,Jim Cramer Interviews CEO Ron Cohen of Acor Therapeutics on Mad Money,2013-01-09 18:19:00-05:00,ACOR,negative
18913.0,"From Earlier: MKM Partners Downgrades Acorda Therapeutics, Inc. to Neutral",2013-01-08 11:16:00-05:00,ACOR,neutral
18914.0,"UPDATE: Acorda Sees 2013 Other Sales ~$25M (Fampyra, Zanaflex)",2013-01-07 14:00:00-05:00,ACOR,neutral
18915.0,Acorda Therapeutics Sees 2013 Ampyra US Net Sales $285-315M,2013-01-07 14:00:00-05:00,ACOR,neutral
18916.0,"UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts  ",2013-01-03 08:26:00-05:00,ACOR,negative
18917.0,"Citigroup Upgrades Acorda Therapeutics, Inc. to Buy, Raises PT to $33.00",2013-01-03 07:15:00-05:00,ACOR,neutral
18918.0,A Peek Into The Market Before The Trading Starts,2012-12-21 07:17:00-05:00,ACOR,neutral
18919.0,Acorda Therapeutics  Completes Neuronex Acquisition ,2012-12-21 06:16:00-05:00,ACOR,neutral
18920.0,"Aegis Capital Maintains Acorda Therapeutics at Buy, Raises PT from $32 to $34",2012-11-05 15:57:00-05:00,ACOR,neutral
18921.0,Acorda Therapeutics Reports Q3 EPS $0.38 vs $0.10 Est; Revenues $77.4M vs $75.20M Est,2012-10-31 06:53:00-04:00,ACOR,neutral
18922.0,Acorda Spikes Lower,2012-10-24 14:23:00-04:00,ACOR,negative
18923.0,Acorda Therapeutics Spikes Higher,2012-10-12 14:02:00-04:00,ACOR,neutral
18924.0,"Acorda Therapeutics Names Jane Wasman President, International ",2012-10-09 06:39:00-04:00,ACOR,neutral
18925.0,Acorda Therapeutics Falls 4%; Hearing Group Health Negative Report on Ampyra ,2012-10-08 10:34:00-04:00,ACOR,negative
18926.0,Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction ,2012-08-28 07:05:00-04:00,ACOR,negative
18927.0,UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra Visibility  ,2012-08-21 13:07:00-04:00,ACOR,neutral
18928.0,"Aegis Capital Initiates Coverage on Acorda Therapeutics at Buy, Announces PT of $32",2012-08-21 07:16:00-04:00,ACOR,neutral
18929.0,Benzinga's Top Pre-Market Gainers,2012-08-13 08:21:00-04:00,ACOR,positive
18930.0,"Option Alert: Acorda Therapeutics Call Volume at 1,678% of Average; Currently $22.61",2012-08-02 13:50:00-04:00,ACOR,positive
18931.0,Acorda Therapeutics Reports Q2 EPS $0.27 vs $0.12 Est; Revenues $75.7M vs $72.55M Est,2012-07-31 07:33:00-04:00,ACOR,neutral
18932.0,FDA Warns of Seizure Risk in MS Patients Taking Acorda's Ampyra,2012-07-23 11:48:00-04:00,ACOR,negative
18933.0,Leerink Swann Resumes Coverage on Acorda Therapeutics at Outperform,2012-07-23 08:22:00-04:00,ACOR,neutral
18934.0,Acorda CEO Cohen: 'Our Challenge Going Forward is to Make Sure Enough People with MS Know about Our Drug',2012-06-19 18:51:00-04:00,ACOR,positive
18935.0,Acorda CEO Cohen: 'We Project We Will See Between $225M and $275M in Sales This Year for Ampyra',2012-06-19 18:50:00-04:00,ACOR,neutral
18936.0,Acorda CEO Cohen: 'There are a Lot of People with MS Who Have Not Tried Ampyra',2012-06-19 18:48:00-04:00,ACOR,neutral
18937.0,Jim Cramer Interviews CEO Dr. Ron Cohen of Acorda Therapeutics on Mad Money,2012-06-19 18:45:00-04:00,ACOR,negative
18938.0,From Earlier: Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits  ,2012-06-12 09:19:00-04:00,ACOR,neutral
18939.0,A Peek Into The Market Before The Trading Starts,2012-06-12 07:33:00-04:00,ACOR,neutral
18940.0,Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits   ,2012-06-12 07:19:00-04:00,ACOR,neutral
18941.0,Appeals Court Upholds Patent Decision Against Acorda Therapeutics -Bloomberg,2012-06-11 12:08:00-04:00,ACOR,neutral
18942.0,UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk  ,2012-05-18 12:50:00-04:00,ACOR,negative
18943.0,"Goldman Sachs Initiates Coverage on Acorda Therapeutics at Sell, Announces PT of $21",2012-05-18 06:35:00-04:00,ACOR,neutral
18944.0,Acorda Therapeutics Reports Q1 EPS $0.36 vs $0.18 Est; Revenues $71.2M vs $70.95M Est,2012-05-03 06:51:00-04:00,ACOR,neutral
18945.0,Acorda Therapeutics Spiking Higher on Heavy Volume; Currently at $26.21,2012-03-15 12:16:00-04:00,ACOR,neutral
18946.0,"UPDATE: Stifel Nicolaus Resumes Buy, $34 Target on Acorda Therapeutics",2012-03-15 11:31:00-04:00,ACOR,neutral
18947.0,"Citigroup Downgrades Acorda Therapeutics from Buy to Neutral, Raises PT from $27 to $29",2012-02-17 06:05:00-05:00,ACOR,neutral
18948.0,Acorda Therapeutics Reports Q4 EPS $0.45 vs $0.18 Est; Revenues $72.6M vs $69.16M Est	 		,2012-02-16 06:41:00-05:00,ACOR,neutral
18949.0,Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX CAPSULES®,2012-02-06 16:15:00-05:00,ACOR,neutral
18950.0,"Apotex Receives FDA Approval, Negative for Acorda Therapeutics ",2012-02-06 15:03:00-05:00,ACOR,negative
18951.0,Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves Motor Function in Chronic Stroke   ,2012-02-03 07:01:00-05:00,ACOR,positive
18952.0,"JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM",2012-01-23 07:48:00-05:00,ACOR,positive
18953.0,Disclosure Insight Maintains Medium Risk Rating on Acorda Therapeutics ,2011-11-15 06:35:00-05:00,ACOR,negative
18954.0,Piper Jaffray Neutral on Acorda Therapeutics ,2011-11-07 07:41:00-05:00,ACOR,neutral
18955.0,"Rodman & Renshaw Reiterates Acorda Therapeutics Market Underperform, $18 PT",2011-11-04 15:05:00-04:00,ACOR,neutral
18956.0,Earnings Scheduled For November 4,2011-11-04 03:54:00-04:00,ACOR,neutral
18957.0,Piper Jaffray Maintains Neutral Rating and $28 PT on Acorda Therapeutics ,2011-10-21 08:48:00-04:00,ACOR,neutral
18958.0,Notable Call Options Activity in Acorda Therapeutics,2011-10-13 13:48:00-04:00,ACOR,neutral
18959.0,JP Morgan Lowers PT On Acorda Therapeutics To $38,2011-09-07 09:04:00-04:00,ACOR,positive
18960.0,Acorda Therapeutics Statement on ZANAFLEX CAPSULES Patent Litigation  ,2011-09-07 06:55:00-04:00,ACOR,negative
18961.0,A Peek Into The Market Before The Trading Starts,2011-08-10 07:36:00-04:00,ACOR,neutral
18962.0,Acorda Therapeutics Announces Allowance of Second U.S. Patent Application for AMPYRA® Covering Methods of Use for Improving Walking in Multiple Sclerosis ,2011-08-10 06:50:00-04:00,ACOR,positive
18963.0,UPDATE: Piper Jaffray Lowering Price Target On Acorda Therapeutics  ,2011-08-02 07:31:00-04:00,ACOR,negative
18964.0,Piper Jaffray Lowers PT On Acorda Therapeutics To $28,2011-08-02 06:26:00-04:00,ACOR,negative
18965.0,"Rodman & Renshaw Maintains Acorda Therapeutics Market Underperform, $18 PT",2011-08-01 15:53:00-04:00,ACOR,neutral
18966.0,Earnings Roundup,2011-08-01 08:34:00-04:00,ACOR,neutral
18967.0,UPDATE: Acorda Therapeutics Reports Weaker-Than-Expected Q2 Earnings,2011-08-01 07:26:00-04:00,ACOR,neutral
18968.0,Earnings Scheduled For August 1,2011-08-01 03:31:00-04:00,ACOR,neutral
18969.0,11 Stocks Breaking Down,2011-07-11 14:25:00-04:00,ACOR,neutral
18970.0,A Peek Into The Market Before The Trading Starts,2011-07-01 07:37:00-04:00,ACOR,neutral
18971.0,Acorda Therapeutics Licenses Rights to Investigational Treatment for Spinal Cord Injury and Traumatic Brain Injury   ,2011-07-01 07:01:00-04:00,ACOR,negative
18972.0,"Calls Purchased on Acorda Therapeutics, Inc.",2011-06-21 11:09:00-04:00,ACOR,neutral
18973.0,Trade Setups For 6/21,2011-06-20 22:01:00-04:00,ACOR,neutral
18974.0,Acorda Therapeutics Jumping On Takeover Rumors,2011-06-07 13:38:00-04:00,ACOR,neutral
18975.0,Hearing Chatter Biogen May Buy/Partner On MS Drugs,2011-06-07 13:31:00-04:00,ACOR,neutral
18976.0,Acorda Therapeutics Spiking on Heavy Volume,2011-06-07 13:29:00-04:00,ACOR,neutral
18977.0,New Clinical Data Analysis of AMPYRA Shows Improvement of Patient-Reported Walking Ability across a Range of Walking Impairment ,2011-06-06 07:09:00-04:00,ACOR,positive
18978.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,ACOR,positive
18979.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,ACOR,negative
18980.0,Puts Purchased on Acorda Therapeutics,2011-05-25 15:23:00-04:00,ACOR,neutral
18981.0,Benzinga's Top Upgrades,2011-05-23 08:16:00-04:00,ACOR,positive
18982.0,UPDATE: Piper Jaffray Upgrading Acorda Therapeutics  ,2011-05-23 07:33:00-04:00,ACOR,neutral
18983.0,"Piper Jaffray Upgrades Acorda Therapeutics To Neutral, PT Raised To $30",2011-05-23 05:48:00-04:00,ACOR,neutral
18984.0,Benzinga's Top Pre-Market NASDAQ Gainers,2011-05-20 08:17:00-04:00,ACOR,positive
18985.0,EMA Panel Seeks Long-Term Efficacy Study Of Fampyra -Bloomberg,2011-05-20 07:18:00-04:00,ACOR,neutral
18986.0,Consumer Now in Question  05-16-2011,2011-05-16 19:03:00-04:00,ACOR,neutral
18987.0,Stifel Nicolaus Has Hold Rating On Acorda Therapeutics  (ACOR),2011-04-15 13:00:00-04:00,ACOR,neutral
18988.0,Acorda Therapeutics Up 2.5% (ACOR),2011-04-15 09:04:00-04:00,ACOR,neutral
18989.0,Acorda Therapeutics Closed Significantly Higher Thursday (ACOR),2011-04-15 07:20:00-04:00,ACOR,neutral
18990.0,ACOR Resumes Trading (ACOR),2011-04-15 07:11:00-04:00,ACOR,neutral
18991.0,"Acorda Therapeutics Halted, News Pending (ACOR)",2011-04-14 13:59:00-04:00,ACOR,neutral
18992.0,Hearing Acorda Therapeutics Spike Due To FDA Related News (ACOR),2011-04-14 13:41:00-04:00,ACOR,neutral
18993.0,"Friday's Put/Call Ratio Leaders (ACOR, IT, RDC, GGB, BID)",2011-02-18 12:46:00-05:00,ACOR,neutral
18994.0,Options Brief: Acorda Therapeutics (ACOR),2011-02-18 11:51:00-05:00,ACOR,neutral
18995.0,UPDATE: Hapoalim Securities Upgrades Acorda Therapeutics To Hold; Raises PT,2011-02-18 10:53:00-05:00,ACOR,positive
18996.0,"Piper Jaffray Downgrades Acorda Therapeutics, Lowers PT To $16 (ACOR)",2011-02-18 09:06:00-05:00,ACOR,negative
18997.0,"Benzinga's Top Downgrades (VCLK, ACOR, SMI, CAB)",2011-02-18 07:53:00-05:00,ACOR,positive
18998.0,"Piper Jaffray Downgrades Acorda Therapeutics To Underweight, PT To $16",2011-02-18 07:48:00-05:00,ACOR,neutral
18999.0,SAC Capital Takes 5.6% Stake In Acorda Therapeutics (ACOR),2011-01-31 16:17:00-05:00,ACOR,neutral
19000.0,Biogen-Acorda MS Drug Faces Setback - Analyst Blog,2011-01-24 12:31:00-05:00,ACOR,neutral
19001.0,Biogen-Acorda MS Drug Faces Setback - Analyst Blog,2011-01-24 11:45:00-05:00,ACOR,neutral
19002.0,Piper Jaffray Lowers PT on Acorda Therapeutics Following EU Setback,2011-01-24 08:37:00-05:00,ACOR,negative
19003.0,Hapoalim Reiterates Sell on Acorda Therapeutics (ACOR),2011-01-24 07:13:00-05:00,ACOR,neutral
19004.0,Piper Jaffray Lowers PT On Acorda Therapeutics,2011-01-24 06:56:00-05:00,ACOR,negative
19005.0,"Benzinga's Top Pre-Market NASDAQ Losers (ACOR, VVUS, SYNA, MNKD)",2011-01-21 08:35:00-05:00,ACOR,negative
19006.0,Ampyra Supports Acorda Yet Again - Analyst Blog,2011-01-11 17:32:00-05:00,ACOR,positive
19007.0,Ampyra Supports Acorda Yet Again - Analyst Blog,2011-01-11 16:55:00-05:00,ACOR,positive
19008.0,Accorda Therapeutics Rises 10% (ACOR),2011-01-10 15:52:00-05:00,ACOR,neutral
19009.0,Acorda Therapeutics Up 8.8% On Sales News (ACOR),2011-01-10 14:56:00-05:00,ACOR,neutral
19010.0,"Benzinga's Volume Movers (ACOR, AUXL, MDSO, SONO)",2011-01-10 11:12:00-05:00,ACOR,neutral
19011.0,Options Brief: Acorda Therapeutics (ACOR),2011-01-10 11:01:00-05:00,ACOR,neutral
19012.0,Biogen Strikes Deal with Neurimmune - Analyst Blog,2010-12-21 08:33:00-05:00,ACOR,negative
19013.0,Biogen Strikes Deal with Neurimmune - Analyst Blog,2010-12-21 08:15:00-05:00,ACOR,negative
19014.0,"BP: Analysts' Upgrades, Downgrades",2010-12-14 08:39:00-05:00,ACOR,neutral
19015.0,J.P. Morgan Reiterates Overweight Rating on Acorda Therapeutics (ACOR),2010-12-03 10:03:00-05:00,ACOR,negative
19016.0,Positive Data on Acorda's Ampyra - Analyst Blog,2010-11-23 17:36:00-05:00,ACOR,positive
19017.0,Positive Data on Acorda's Ampyra - Analyst Blog,2010-11-23 11:51:00-05:00,ACOR,positive
19018.0,Acorda Profit Soars on Ampyra Sales - Analyst Blog,2010-11-05 09:33:00-04:00,ACOR,positive
19019.0,Citigroup Expects Acorda Therapeutics To Be Profitable,2010-11-02 07:59:00-04:00,ACOR,positive
19020.0,Hapoalim Securities Downgrades Acorda Therapeutics (ACOR),2010-11-01 13:16:00-04:00,ACOR,positive
19021.0,Acorda Therapeutics Shares Fall 4.4% Despite Results (ACOR),2010-11-01 12:45:00-04:00,ACOR,positive
19022.0,Acorda Therapeutics Blows By Estimates (ACOR),2010-11-01 09:29:00-04:00,ACOR,neutral
19023.0,Zacks #1 Rank Additions for Tuesday - Tale of the Tape,2010-10-19 08:39:00-04:00,ACOR,neutral
19024.0,Hapoalim Securities Lowers Price Target on Acorda Therapeutics (ACOR),2010-10-15 10:01:00-04:00,ACOR,positive
19025.0,"Prior To 3Q Earnings, J.P. Morgan Rates The Best In Biotechnology",2010-10-15 07:41:00-04:00,ACOR,positive
19026.0,Biogen Cut to Neutral - Analyst Blog,2010-10-03 19:30:00-04:00,ACOR,negative
19027.0,Acorda Loss Narrows on Ampyra Revs - Analyst Blog,2010-08-04 13:34:00-04:00,ACOR,negative
19028.0,Hapoalim Securities Has $37 Price Target On Acorda (ACOR),2010-08-04 09:34:00-04:00,ACOR,positive
19029.0,Hapoalim Securities Downgrades Acorda Therapeutics to Hold (ACOR),2010-07-19 14:43:00-04:00,ACOR,positive
19030.0,Protection Purchased on Acorda Therapeutics (ACOR),2010-06-23 12:29:00-04:00,ACOR,neutral
19031.0,Citigroup Maintains Hold Rating On Acorda Therapeutics (ACOR),2010-06-04 16:55:00-04:00,ACOR,neutral
19032.0,"Stocks That Have Crossed 52-Week Highs (ACOR, ACTL, AMZN, ARII, AAPL)",2010-04-15 16:19:00-04:00,ACOR,neutral
19033.0,Heavy Volume In Acorda Therapeutics (ACOR),2010-04-15 11:17:00-04:00,ACOR,neutral
19034.0,"Stocks That Created New 52-Week Highs (AAON, ACOR, ADTN, ADVS, ATSG)",2010-04-14 15:28:00-04:00,ACOR,positive
19035.0,ACOR Initiated With Hold At Citigroup,2010-03-29 09:14:00-04:00,ACOR,neutral
19036.0,Reduce Your Risk In The Initial Public Offering Market With This IPO ETF,2010-03-25 19:56:00-04:00,ACOR,negative
19037.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,ACOR,positive
19038.0,"Stocks That Created New 52-Week Highs (COMS, ACGY, ACOR, ACTL, ADVS)",2010-03-03 14:52:00-05:00,ACOR,positive
19039.0,Acorda’s Q4 Loss In-Line With Expectations; Plans To Launch MS Drug In March (ACOR),2010-02-23 12:18:00-05:00,ACOR,negative
19040.0,"Stocks That Created New 52-Week Highs (SMLC, APKT, ACOR, AEHR, BIIB)",2010-02-17 14:53:00-05:00,ACOR,positive
19041.0,"Lightening Round: Jim Enthusiastic About ACOR, RMBS, VM, ERTS, CHU",2010-02-10 08:08:00-05:00,ACOR,positive
19042.0,"Analyst Shares Top Picks In Biotechnology Sector With CNBC (AMGN, ACOR, DNDN, GILD)",2010-02-09 08:13:00-05:00,ACOR,positive
19043.0,Acorda (ACOR) Announces Ampyra Pricing,2010-02-04 05:46:00-05:00,ACOR,neutral
19044.0,"Benzinga’s Volume Movers (APKT, AUXL, NETL, MYGN, ACOR)",2010-02-03 14:08:00-05:00,ACOR,neutral
19045.0,Acorda Therapeutics Rallying On Heavy Volume (ACOR),2010-02-02 13:32:00-05:00,ACOR,neutral
19046.0,ACOR Added To JP Morgan US Analyst Focus List,2010-02-02 13:22:00-05:00,ACOR,positive
19047.0,"Benzinga’s Top Pre-Market Losers (PARD, DLTR, GENZ, SNDA, ACOR, TTHI, HCBK)",2010-01-25 08:44:00-05:00,ACOR,negative
19048.0,Mid Cap Biotechs May Outperform In 2010,2010-01-15 14:11:00-05:00,ACOR,neutral
19049.0,"Healthcare sector boom, predicts, Oracle hedge fund chief (THC, CEPH, ACOR)",2009-11-02 13:08:00-05:00,ACOR,neutral
19050.0,"Acorda Therapeutics  (ACOR)  To Announce 2009 Q3  Financial Results on November 3,2009",2009-10-27 08:07:00-04:00,ACOR,neutral
19051.0,"Biggest Losers (SPPI, ACOR, LEAP, LXRX, CLRT)",2009-10-09 11:45:00-04:00,ACOR,negative
